RE:Let’s see if we picked the right COVID horsegimmycash wrote: So far Sona in the lead by far with no revs only a test and a dream,will we be the first to report multi million dollar revenue.and where will the sp land if so.
IMO Sona is an anomaly. When $16 hit, that was a 160,000% increase from December 2019 when the Sp was one penny. Had and sold, albeit at a much lower share price than current. The volatility is reminiscent of pot stocks in the day. MIR, 400,000 plus shares are owned by insiders. For those that post here saying SZLS is late to the covid game, other covid sticks have popped, szls was never a covid company. They are busy proving they are masters in class of laboratory accuracy, building a new foundation with newfound partners and using the money generated by covid testing to launch Aristotle into the market place. We have bases in Toronto and Virginia, American interests have always leaned towards companies conducting business on American soil. Back to Sona, while their test holds promise, they have not submitted an application to the FDA pending completion of clinical trials. MIR has submitted, pending notification. The Sp at Sona is certainly able to see a run similar to TLRY a few years back, lesser shares out, thus the run from IPO of $17, to $300 in a matter of weeks. That said, BIO tech can have similar possibilities. Using stop losses and specifically trailing stop losses in stocks that are moving is a safe bet. It is my hope that James has seemingly turned a new leaf and at this stage of his career, can feel his time of being. To leave a legacy behind and a dramatic turnaround in a career that met many shortcomings, perhaps at times a victim of circumstance and much larger money controlling outcomes and thwarting ideals and dreams. Now is the time Mr. Tripp. And Mr. Tripp feels it. It is now time to shine. Good luck to us all. VM.